ZA200301013B - Bicyclic pyrrolyl amides as glucogen phosphorylase inhibitors. - Google Patents
Bicyclic pyrrolyl amides as glucogen phosphorylase inhibitors. Download PDFInfo
- Publication number
- ZA200301013B ZA200301013B ZA200301013A ZA200301013A ZA200301013B ZA 200301013 B ZA200301013 B ZA 200301013B ZA 200301013 A ZA200301013 A ZA 200301013A ZA 200301013 A ZA200301013 A ZA 200301013A ZA 200301013 B ZA200301013 B ZA 200301013B
- Authority
- ZA
- South Africa
- Prior art keywords
- carbamoyl
- thieno
- pyrrole
- dichloro
- amino
- Prior art date
Links
- -1 Bicyclic pyrrolyl amides Chemical class 0.000 title claims description 287
- 239000003112 inhibitor Substances 0.000 title description 3
- 102000009097 Phosphorylases Human genes 0.000 title description 2
- 108010073135 Phosphorylases Proteins 0.000 title description 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 128
- 125000000217 alkyl group Chemical group 0.000 claims description 79
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 62
- 229910052739 hydrogen Inorganic materials 0.000 claims description 54
- 239000001257 hydrogen Substances 0.000 claims description 52
- 125000000623 heterocyclic group Chemical group 0.000 claims description 40
- 150000001875 compounds Chemical class 0.000 claims description 38
- 229910052757 nitrogen Inorganic materials 0.000 claims description 38
- 125000005843 halogen group Chemical group 0.000 claims description 29
- 229910052799 carbon Inorganic materials 0.000 claims description 27
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 25
- 125000003118 aryl group Chemical group 0.000 claims description 25
- 150000002431 hydrogen Chemical class 0.000 claims description 25
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 24
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 24
- 150000003839 salts Chemical class 0.000 claims description 23
- 150000002148 esters Chemical class 0.000 claims description 22
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 22
- 125000001951 carbamoylamino group Chemical group C(N)(=O)N* 0.000 claims description 19
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 19
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 18
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 14
- 238000001727 in vivo Methods 0.000 claims description 13
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 13
- 102000007390 Glycogen Phosphorylase Human genes 0.000 claims description 12
- 108010046163 Glycogen Phosphorylase Proteins 0.000 claims description 12
- 125000003545 alkoxy group Chemical group 0.000 claims description 12
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 12
- 125000003342 alkenyl group Chemical group 0.000 claims description 11
- 229910052717 sulfur Inorganic materials 0.000 claims description 11
- 125000001072 heteroaryl group Chemical group 0.000 claims description 10
- 125000000304 alkynyl group Chemical group 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 9
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 claims description 9
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims description 8
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 8
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 claims description 8
- 125000004656 alkyl sulfonylamino group Chemical group 0.000 claims description 7
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 claims description 7
- 230000002401 inhibitory effect Effects 0.000 claims description 7
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims description 7
- 229910052760 oxygen Inorganic materials 0.000 claims description 7
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 claims description 6
- 125000005002 aryl methyl group Chemical group 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 229910052698 phosphorus Inorganic materials 0.000 claims description 6
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 6
- 241001465754 Metazoa Species 0.000 claims description 5
- 125000004466 alkoxycarbonylamino group Chemical group 0.000 claims description 5
- 125000001589 carboacyl group Chemical group 0.000 claims description 5
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 5
- 125000003107 substituted aryl group Chemical group 0.000 claims description 5
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 4
- 125000004423 acyloxy group Chemical group 0.000 claims description 4
- 125000005236 alkanoylamino group Chemical group 0.000 claims description 4
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 claims description 4
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 claims description 4
- 239000005864 Sulphur Substances 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 2
- 125000004432 carbon atom Chemical group C* 0.000 claims description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 2
- 239000001301 oxygen Substances 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 claims 11
- 239000000203 mixture Substances 0.000 claims 10
- 239000000126 substance Substances 0.000 claims 8
- 125000004130 indan-2-yl group Chemical group [H]C1=C([H])C([H])=C2C(=C1[H])C([H])([H])C([H])(*)C2([H])[H] 0.000 claims 2
- UYGMKKAFEMEBKS-UHFFFAOYSA-N 2,3-dichloro-n-(1-hydroxy-2,3-dihydro-1h-inden-2-yl)-4h-thieno[3,2-b]pyrrole-5-carboxamide Chemical compound C1=CC=C2C(O)C(NC(=O)C=3NC=4C(Cl)=C(Cl)SC=4C=3)CC2=C1 UYGMKKAFEMEBKS-UHFFFAOYSA-N 0.000 claims 1
- FSFFDXIWVZJNNU-UHFFFAOYSA-N 2,3-dichloro-n-(1-hydroxy-3-phenylpropan-2-yl)-4h-thieno[3,2-b]pyrrole-5-carboxamide Chemical compound C=1C=2SC(Cl)=C(Cl)C=2NC=1C(=O)NC(CO)CC1=CC=CC=C1 FSFFDXIWVZJNNU-UHFFFAOYSA-N 0.000 claims 1
- JUWTUIBOKUUITD-UHFFFAOYSA-N 2,3-dichloro-n-(1-methoxy-2,3-dihydro-1h-inden-2-yl)-4h-thieno[3,2-b]pyrrole-5-carboxamide Chemical compound C1=CC=C2C(OC)C(NC(=O)C=3NC=4C(Cl)=C(Cl)SC=4C=3)CC2=C1 JUWTUIBOKUUITD-UHFFFAOYSA-N 0.000 claims 1
- JATXYZPMRXZLHH-UHFFFAOYSA-N 2,3-dichloro-n-(2,3-dihydro-1h-inden-2-yl)-4h-thieno[3,2-b]pyrrole-5-carboxamide Chemical compound C1C2=CC=CC=C2CC1NC(=O)C1=CC(SC(=C2Cl)Cl)=C2N1 JATXYZPMRXZLHH-UHFFFAOYSA-N 0.000 claims 1
- BZWIVNBVZLWQSN-UHFFFAOYSA-N 2,3-dichloro-n-(2-morpholin-4-yl-2-oxoethyl)-4h-thieno[3,2-b]pyrrole-5-carboxamide Chemical compound N1C=2C(Cl)=C(Cl)SC=2C=C1C(=O)NCC(=O)N1CCOCC1 BZWIVNBVZLWQSN-UHFFFAOYSA-N 0.000 claims 1
- MDPWYSDLLSYTBU-UHFFFAOYSA-N 2,3-dichloro-n-(2-oxo-2-thiomorpholin-4-ylethyl)-4h-thieno[3,2-b]pyrrole-5-carboxamide Chemical compound N1C=2C(Cl)=C(Cl)SC=2C=C1C(=O)NCC(=O)N1CCSCC1 MDPWYSDLLSYTBU-UHFFFAOYSA-N 0.000 claims 1
- DPEDUCZSPJJIQI-UHFFFAOYSA-N 2,3-dichloro-n-(2-phenoxyethyl)-4h-thieno[3,2-b]pyrrole-5-carboxamide Chemical compound N1C=2C(Cl)=C(Cl)SC=2C=C1C(=O)NCCOC1=CC=CC=C1 DPEDUCZSPJJIQI-UHFFFAOYSA-N 0.000 claims 1
- OLVIPIFAMYRLRW-UHFFFAOYSA-N 2,3-dichloro-n-(2-phenylcyclopropyl)-4h-thieno[3,2-b]pyrrole-5-carboxamide Chemical compound N1C=2C(Cl)=C(Cl)SC=2C=C1C(=O)NC1CC1C1=CC=CC=C1 OLVIPIFAMYRLRW-UHFFFAOYSA-N 0.000 claims 1
- LKAMUERYPRRVDB-UHFFFAOYSA-N 2,3-dichloro-n-(2-phenylethyl)-4h-thieno[3,2-b]pyrrole-5-carboxamide Chemical compound N1C=2C(Cl)=C(Cl)SC=2C=C1C(=O)NCCC1=CC=CC=C1 LKAMUERYPRRVDB-UHFFFAOYSA-N 0.000 claims 1
- LKYXKTBZJHVQIR-UHFFFAOYSA-N 2,3-dichloro-n-(6-fluoro-1-hydroxy-2,3-dihydro-1h-inden-2-yl)-4h-thieno[3,2-b]pyrrole-5-carboxamide Chemical compound C1=C(F)C=C2C(O)C(NC(=O)C=3NC=4C(Cl)=C(Cl)SC=4C=3)CC2=C1 LKYXKTBZJHVQIR-UHFFFAOYSA-N 0.000 claims 1
- UYGMKKAFEMEBKS-YMTOWFKASA-N 2,3-dichloro-n-[(1r,2r)-1-hydroxy-2,3-dihydro-1h-inden-2-yl]-4h-thieno[3,2-b]pyrrole-5-carboxamide Chemical compound C1=CC=C2[C@@H](O)[C@H](NC(=O)C=3NC=4C(Cl)=C(Cl)SC=4C=3)CC2=C1 UYGMKKAFEMEBKS-YMTOWFKASA-N 0.000 claims 1
- RWMLUGDXHFKJAX-UHFFFAOYSA-N 2,3-dichloro-n-[(4-phenyl-1,2-oxazol-3-yl)methyl]-4h-thieno[3,2-b]pyrrole-5-carboxamide Chemical compound N1C=2C(Cl)=C(Cl)SC=2C=C1C(=O)NCC1=NOC=C1C1=CC=CC=C1 RWMLUGDXHFKJAX-UHFFFAOYSA-N 0.000 claims 1
- LYCQTQJFUNMFHJ-UHFFFAOYSA-N 2,3-dichloro-n-[(4-sulfamoylphenyl)methyl]-4h-thieno[3,2-b]pyrrole-5-carboxamide Chemical compound C1=CC(S(=O)(=O)N)=CC=C1CNC(=O)C(N1)=CC2=C1C(Cl)=C(Cl)S2 LYCQTQJFUNMFHJ-UHFFFAOYSA-N 0.000 claims 1
- DXXKGUQVNUYWAW-UHFFFAOYSA-N 2,3-dichloro-n-[1-(methylamino)-2,3-dihydro-1h-inden-2-yl]-4h-thieno[3,2-b]pyrrole-5-carboxamide Chemical compound C1=CC=C2C(NC)C(NC(=O)C=3NC=4C(Cl)=C(Cl)SC=4C=3)CC2=C1 DXXKGUQVNUYWAW-UHFFFAOYSA-N 0.000 claims 1
- VRACKEYFARMVJV-UHFFFAOYSA-N 2,3-dichloro-n-[2-(3-methoxyphenyl)ethyl]-4h-thieno[3,2-b]pyrrole-5-carboxamide Chemical compound COC1=CC=CC(CCNC(=O)C=2NC=3C(Cl)=C(Cl)SC=3C=2)=C1 VRACKEYFARMVJV-UHFFFAOYSA-N 0.000 claims 1
- SHGWMYYVPRFEMP-UHFFFAOYSA-N 2,3-dichloro-n-[2-(4-fluorophenyl)ethyl]-4h-thieno[3,2-b]pyrrole-5-carboxamide Chemical compound C1=CC(F)=CC=C1CCNC(=O)C(N1)=CC2=C1C(Cl)=C(Cl)S2 SHGWMYYVPRFEMP-UHFFFAOYSA-N 0.000 claims 1
- ZIBLKQVZWYTBLM-UHFFFAOYSA-N 2,3-dichloro-n-[2-(pyridin-2-ylamino)ethyl]-4h-thieno[3,2-b]pyrrole-5-carboxamide Chemical compound N1C=2C(Cl)=C(Cl)SC=2C=C1C(=O)NCCNC1=CC=CC=N1 ZIBLKQVZWYTBLM-UHFFFAOYSA-N 0.000 claims 1
- BUATVCVONAUNMU-UHFFFAOYSA-N 2,3-dichloro-n-[2-[2-(2-morpholin-4-yl-2-oxoethoxy)phenyl]ethyl]-4h-thieno[3,2-b]pyrrole-5-carboxamide Chemical compound N1C=2C(Cl)=C(Cl)SC=2C=C1C(=O)NCCC1=CC=CC=C1OCC(=O)N1CCOCC1 BUATVCVONAUNMU-UHFFFAOYSA-N 0.000 claims 1
- VGNDCLZZIZKUOV-UHFFFAOYSA-N 2,3-dichloro-n-[2-[2-(hydroxymethyl)phenyl]ethyl]-4h-thieno[3,2-b]pyrrole-5-carboxamide Chemical compound OCC1=CC=CC=C1CCNC(=O)C(N1)=CC2=C1C(Cl)=C(Cl)S2 VGNDCLZZIZKUOV-UHFFFAOYSA-N 0.000 claims 1
- NVSMDIROKXNRSW-UHFFFAOYSA-N 2,3-dichloro-n-[2-[2-[2-(4-hydroxypiperidin-1-yl)-2-oxoethoxy]phenyl]ethyl]-4h-thieno[3,2-b]pyrrole-5-carboxamide Chemical compound C1CC(O)CCN1C(=O)COC1=CC=CC=C1CCNC(=O)C(N1)=CC2=C1C(Cl)=C(Cl)S2 NVSMDIROKXNRSW-UHFFFAOYSA-N 0.000 claims 1
- VYLACUTZKRPLNY-UHFFFAOYSA-N 2,3-dichloro-n-[2-[2-[2-(dimethylamino)-2-oxoethoxy]phenyl]ethyl]-4h-thieno[3,2-b]pyrrole-5-carboxamide Chemical compound CN(C)C(=O)COC1=CC=CC=C1CCNC(=O)C(N1)=CC2=C1C(Cl)=C(Cl)S2 VYLACUTZKRPLNY-UHFFFAOYSA-N 0.000 claims 1
- XHJSBLVLKRHMLV-UHFFFAOYSA-N 2,3-dichloro-n-[3-(2h-tetrazol-5-yl)propyl]-4h-thieno[3,2-b]pyrrole-5-carboxamide Chemical compound N1C=2C(Cl)=C(Cl)SC=2C=C1C(=O)NCCCC1=NN=NN1 XHJSBLVLKRHMLV-UHFFFAOYSA-N 0.000 claims 1
- MSJVUARALWRDGD-UHFFFAOYSA-N 2,3-dichloro-n-[[6-(trifluoromethyl)pyridin-3-yl]methyl]-4h-thieno[3,2-b]pyrrole-5-carboxamide Chemical compound C1=NC(C(F)(F)F)=CC=C1CNC(=O)C(N1)=CC2=C1C(Cl)=C(Cl)S2 MSJVUARALWRDGD-UHFFFAOYSA-N 0.000 claims 1
- ZWDZEGPABRRQRL-UHFFFAOYSA-N 2,3-dichloro-n-imidazo[1,2-a]pyridin-2-yl-4h-thieno[3,2-b]pyrrole-5-carboxamide Chemical compound C1=CC=CC2=NC(NC(=O)C3=CC=4SC(=C(C=4N3)Cl)Cl)=CN21 ZWDZEGPABRRQRL-UHFFFAOYSA-N 0.000 claims 1
- NQDKMZZPUJRMFX-UHFFFAOYSA-N 2,3-dichloro-n-phenacyl-4h-thieno[3,2-b]pyrrole-5-carboxamide Chemical compound N1C=2C(Cl)=C(Cl)SC=2C=C1C(=O)NCC(=O)C1=CC=CC=C1 NQDKMZZPUJRMFX-UHFFFAOYSA-N 0.000 claims 1
- NLJLTGAIWNDJGI-UHFFFAOYSA-N 2-[2-[2-[(2,3-dichloro-4h-thieno[3,2-b]pyrrole-5-carbonyl)amino]ethyl]phenoxy]acetic acid Chemical compound OC(=O)COC1=CC=CC=C1CCNC(=O)C(N1)=CC2=C1C(Cl)=C(Cl)S2 NLJLTGAIWNDJGI-UHFFFAOYSA-N 0.000 claims 1
- 125000004174 2-benzimidazolyl group Chemical group [H]N1C(*)=NC2=C([H])C([H])=C([H])C([H])=C12 0.000 claims 1
- LRHOLHTVXXSIMG-UHFFFAOYSA-N 2-chloro-n-(1-hydroxy-2,3-dihydro-1h-inden-2-yl)-6h-thieno[2,3-b]pyrrole-5-carboxamide Chemical compound C1=CC=C2C(O)C(NC(=O)C=3NC=4SC(Cl)=CC=4C=3)CC2=C1 LRHOLHTVXXSIMG-UHFFFAOYSA-N 0.000 claims 1
- AZFSIXJWMGOBIS-UHFFFAOYSA-N 2-chloro-n-(2,3-dihydro-1h-inden-2-yl)-6h-thieno[2,3-b]pyrrole-5-carboxamide Chemical compound C1C2=CC=CC=C2CC1NC(=O)C1=CC(C=C(S2)Cl)=C2N1 AZFSIXJWMGOBIS-UHFFFAOYSA-N 0.000 claims 1
- LZRMALFHJSPUEZ-UHFFFAOYSA-N 2-chloro-n-(2-phenoxyethyl)-4h-thieno[3,2-b]pyrrole-5-carboxamide Chemical compound C=1C=2SC(Cl)=CC=2NC=1C(=O)NCCOC1=CC=CC=C1 LZRMALFHJSPUEZ-UHFFFAOYSA-N 0.000 claims 1
- GAHMFEQLJBSDKE-UHFFFAOYSA-N 2-chloro-n-(2-phenylcyclopropyl)-4h-thieno[3,2-b]pyrrole-5-carboxamide Chemical compound C=1C=2SC(Cl)=CC=2NC=1C(=O)NC1CC1C1=CC=CC=C1 GAHMFEQLJBSDKE-UHFFFAOYSA-N 0.000 claims 1
- QAHLOPCFUHOCLZ-UHFFFAOYSA-N 2-chloro-n-(2-thiomorpholin-4-ylethyl)-4h-thieno[3,2-b]pyrrole-5-carboxamide Chemical compound C=1C=2SC(Cl)=CC=2NC=1C(=O)NCCN1CCSCC1 QAHLOPCFUHOCLZ-UHFFFAOYSA-N 0.000 claims 1
- IKROHIVUCNQKGM-UHFFFAOYSA-N 2-chloro-n-[2-(4-fluorophenyl)ethyl]-4h-thieno[3,2-b]pyrrole-5-carboxamide Chemical compound C1=CC(F)=CC=C1CCNC(=O)C(N1)=CC2=C1C=C(Cl)S2 IKROHIVUCNQKGM-UHFFFAOYSA-N 0.000 claims 1
- FFETWUGJXIAOJT-UHFFFAOYSA-N 2-chloro-n-[2-(pyridin-2-ylamino)ethyl]-4h-thieno[3,2-b]pyrrole-5-carboxamide Chemical compound C=1C=2SC(Cl)=CC=2NC=1C(=O)NCCNC1=CC=CC=N1 FFETWUGJXIAOJT-UHFFFAOYSA-N 0.000 claims 1
- NDIOKJQXEHMGDB-UHFFFAOYSA-N 2-chloro-n-phenacyl-4h-thieno[3,2-b]pyrrole-5-carboxamide Chemical compound C=1C=2SC(Cl)=CC=2NC=1C(=O)NCC(=O)C1=CC=CC=C1 NDIOKJQXEHMGDB-UHFFFAOYSA-N 0.000 claims 1
- SLLCBWHOKBEUCZ-UHFFFAOYSA-N 3-chloro-n-(2-phenoxyethyl)-4h-thieno[3,2-b]pyrrole-5-carboxamide Chemical compound N1C=2C(Cl)=CSC=2C=C1C(=O)NCCOC1=CC=CC=C1 SLLCBWHOKBEUCZ-UHFFFAOYSA-N 0.000 claims 1
- APBGPCAPGLJDQR-UHFFFAOYSA-N 3-chloro-n-(2-phenylcyclopropyl)-4h-thieno[3,2-b]pyrrole-5-carboxamide Chemical compound N1C=2C(Cl)=CSC=2C=C1C(=O)NC1CC1C1=CC=CC=C1 APBGPCAPGLJDQR-UHFFFAOYSA-N 0.000 claims 1
- JNNLMLKOWMOQOI-UHFFFAOYSA-N 3-chloro-n-(2-thiomorpholin-4-ylethyl)-4h-thieno[3,2-b]pyrrole-5-carboxamide Chemical compound N1C=2C(Cl)=CSC=2C=C1C(=O)NCCN1CCSCC1 JNNLMLKOWMOQOI-UHFFFAOYSA-N 0.000 claims 1
- IMMNOFWGJIRZSV-UHFFFAOYSA-N 3-chloro-n-[2-(4-fluorophenyl)ethyl]-4h-thieno[3,2-b]pyrrole-5-carboxamide Chemical compound C1=CC(F)=CC=C1CCNC(=O)C(N1)=CC2=C1C(Cl)=CS2 IMMNOFWGJIRZSV-UHFFFAOYSA-N 0.000 claims 1
- RYZWHPXUBJROJE-UHFFFAOYSA-N 3-chloro-n-phenacyl-4h-thieno[3,2-b]pyrrole-5-carboxamide Chemical compound N1C=2C(Cl)=CSC=2C=C1C(=O)NCC(=O)C1=CC=CC=C1 RYZWHPXUBJROJE-UHFFFAOYSA-N 0.000 claims 1
- DWAIOCIOSRZZHO-UHFFFAOYSA-N 4h-thieno[3,2-b]pyrrole Chemical compound S1C=CC2=C1C=CN2 DWAIOCIOSRZZHO-UHFFFAOYSA-N 0.000 claims 1
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims 1
- 150000003950 cyclic amides Chemical class 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 claims 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims 1
- KYMXBGUBBFKNRL-UHFFFAOYSA-N n-(1-acetamido-2,3-dihydro-1h-inden-2-yl)-2,3-dichloro-4h-thieno[3,2-b]pyrrole-5-carboxamide Chemical compound C1=CC=C2C(NC(=O)C)C(NC(=O)C=3NC=4C(Cl)=C(Cl)SC=4C=3)CC2=C1 KYMXBGUBBFKNRL-UHFFFAOYSA-N 0.000 claims 1
- BMPQTOZEDDKBBV-UHFFFAOYSA-N n-(1-amino-2,3-dihydro-1h-inden-2-yl)-2,3-dichloro-4h-thieno[3,2-b]pyrrole-5-carboxamide Chemical compound C1=CC=C2C(N)C(NC(=O)C=3NC=4C(Cl)=C(Cl)SC=4C=3)CC2=C1 BMPQTOZEDDKBBV-UHFFFAOYSA-N 0.000 claims 1
- YPMRVUOJBIJKJT-UHFFFAOYSA-N n-[1-[acetyl(methyl)amino]-2,3-dihydro-1h-inden-2-yl]-2,3-dichloro-4h-thieno[3,2-b]pyrrole-5-carboxamide Chemical compound C1=CC=C2C(N(C)C(C)=O)C(NC(=O)C=3NC=4C(Cl)=C(Cl)SC=4C=3)CC2=C1 YPMRVUOJBIJKJT-UHFFFAOYSA-N 0.000 claims 1
- LGYMIWAYGWVTKU-UHFFFAOYSA-N n-[2-(benzylsulfonylamino)ethyl]-3-chloro-4h-thieno[3,2-b]pyrrole-5-carboxamide Chemical compound N1C=2C(Cl)=CSC=2C=C1C(=O)NCCNS(=O)(=O)CC1=CC=CC=C1 LGYMIWAYGWVTKU-UHFFFAOYSA-N 0.000 claims 1
- KWTXDUHPTGHLNG-UHFFFAOYSA-N n-[2-[2-(2-amino-2-oxoethoxy)phenyl]ethyl]-2,3-dichloro-4h-thieno[3,2-b]pyrrole-5-carboxamide Chemical compound NC(=O)COC1=CC=CC=C1CCNC(=O)C(N1)=CC2=C1C(Cl)=C(Cl)S2 KWTXDUHPTGHLNG-UHFFFAOYSA-N 0.000 claims 1
- VKWIFFHOFWDMHE-UHFFFAOYSA-N n-benzyl-2,3-dichloro-4h-thieno[3,2-b]pyrrole-5-carboxamide Chemical compound N1C=2C(Cl)=C(Cl)SC=2C=C1C(=O)NCC1=CC=CC=C1 VKWIFFHOFWDMHE-UHFFFAOYSA-N 0.000 claims 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims 1
- 125000004526 pyridazin-2-yl group Chemical group N1N(C=CC=C1)* 0.000 claims 1
- 125000006413 ring segment Chemical group 0.000 claims 1
- PXQLVRUNWNTZOS-UHFFFAOYSA-N sulfanyl Chemical class [SH] PXQLVRUNWNTZOS-UHFFFAOYSA-N 0.000 claims 1
- 125000004495 thiazol-4-yl group Chemical group S1C=NC(=C1)* 0.000 claims 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 9
- 239000008103 glucose Substances 0.000 description 9
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 9
- 206010012601 diabetes mellitus Diseases 0.000 description 7
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 6
- 102000051325 Glucagon Human genes 0.000 description 4
- 108060003199 Glucagon Proteins 0.000 description 4
- 125000001309 chloro group Chemical group Cl* 0.000 description 4
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 4
- 229960004666 glucagon Drugs 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 125000001624 naphthyl group Chemical group 0.000 description 4
- 125000001424 substituent group Chemical group 0.000 description 4
- JPRPJUMQRZTTED-UHFFFAOYSA-N 1,3-dioxolanyl Chemical group [CH]1OCCO1 JPRPJUMQRZTTED-UHFFFAOYSA-N 0.000 description 3
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 3
- 125000002947 alkylene group Chemical group 0.000 description 3
- 125000004429 atom Chemical group 0.000 description 3
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 3
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000004116 glycogenolysis Effects 0.000 description 3
- 230000002440 hepatic effect Effects 0.000 description 3
- 125000002883 imidazolyl group Chemical group 0.000 description 3
- 125000003373 pyrazinyl group Chemical group 0.000 description 3
- 125000004076 pyridyl group Chemical group 0.000 description 3
- 125000005493 quinolyl group Chemical group 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 125000003831 tetrazolyl group Chemical group 0.000 description 3
- 125000000335 thiazolyl group Chemical group 0.000 description 3
- 125000001544 thienyl group Chemical group 0.000 description 3
- 125000005505 thiomorpholino group Chemical group 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 125000005871 1,3-benzodioxolyl group Chemical group 0.000 description 2
- 125000005877 1,4-benzodioxanyl group Chemical group 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- 206010060378 Hyperinsulinaemia Diseases 0.000 description 2
- 206010022489 Insulin Resistance Diseases 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 125000002619 bicyclic group Chemical group 0.000 description 2
- 125000001246 bromo group Chemical group Br* 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Natural products OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229910052736 halogen Inorganic materials 0.000 description 2
- 150000002367 halogens Chemical class 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 2
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 2
- 125000002950 monocyclic group Chemical group 0.000 description 2
- 239000000651 prodrug Substances 0.000 description 2
- 229940002612 prodrug Drugs 0.000 description 2
- 125000002098 pyridazinyl group Chemical group 0.000 description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- NOLHRFLIXVQPSZ-UHFFFAOYSA-N 1,3-thiazolidin-4-one Chemical compound O=C1CSCN1 NOLHRFLIXVQPSZ-UHFFFAOYSA-N 0.000 description 1
- 125000004343 1-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000006017 1-propenyl group Chemical group 0.000 description 1
- 125000000530 1-propynyl group Chemical group [H]C([H])([H])C#C* 0.000 description 1
- HBZHNVUMFPGVHW-UHFFFAOYSA-N 2-chloro-1h-indole Chemical compound C1=CC=C2NC(Cl)=CC2=C1 HBZHNVUMFPGVHW-UHFFFAOYSA-N 0.000 description 1
- ROJNYKZWTOHRNU-UHFFFAOYSA-N 2-chloro-4,5-difluoro-n-[[2-methoxy-5-(methylcarbamoylamino)phenyl]carbamoyl]benzamide Chemical compound CNC(=O)NC1=CC=C(OC)C(NC(=O)NC(=O)C=2C(=CC(F)=C(F)C=2)Cl)=C1 ROJNYKZWTOHRNU-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- GCNTZFIIOFTKIY-UHFFFAOYSA-N 4-hydroxypyridine Chemical compound OC1=CC=NC=C1 GCNTZFIIOFTKIY-UHFFFAOYSA-N 0.000 description 1
- PXRKCOCTEMYUEG-UHFFFAOYSA-N 5-aminoisoindole-1,3-dione Chemical compound NC1=CC=C2C(=O)NC(=O)C2=C1 PXRKCOCTEMYUEG-UHFFFAOYSA-N 0.000 description 1
- KCIZFYCMKPOFOU-UHFFFAOYSA-N 6h-thieno[2,3-b]pyrrole-5-sulfonamide Chemical class C1=CSC2=C1C=C(S(=O)(=O)N)N2 KCIZFYCMKPOFOU-UHFFFAOYSA-N 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 206010051161 Hyperglucagonaemia Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- HXXFSFRBOHSIMQ-VFUOTHLCSA-N alpha-D-glucose 1-phosphate Chemical compound OC[C@H]1O[C@H](OP(O)(O)=O)[C@H](O)[C@@H](O)[C@@H]1O HXXFSFRBOHSIMQ-VFUOTHLCSA-N 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 239000004410 anthocyanin Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 150000004657 carbamic acid derivatives Chemical class 0.000 description 1
- 125000001721 carboxyacetyl group Chemical group 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229910021419 crystalline silicon Inorganic materials 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 208000033679 diabetic kidney disease Diseases 0.000 description 1
- 125000005117 dialkylcarbamoyl group Chemical group 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000004406 elevated intraocular pressure Effects 0.000 description 1
- 125000000031 ethylamino group Chemical group [H]C([H])([H])C([H])([H])N([H])[*] 0.000 description 1
- 125000006260 ethylaminocarbonyl group Chemical group [H]N(C(*)=O)C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 239000000417 fungicide Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000001890 gluconeogenic effect Effects 0.000 description 1
- 229950010772 glucose-1-phosphate Drugs 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- RCCPEORTSYDPMB-UHFFFAOYSA-N hydroxy benzenecarboximidothioate Chemical compound OSC(=N)C1=CC=CC=C1 RCCPEORTSYDPMB-UHFFFAOYSA-N 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000035879 hyperinsulinaemia Effects 0.000 description 1
- 230000003451 hyperinsulinaemic effect Effects 0.000 description 1
- 201000008980 hyperinsulinism Diseases 0.000 description 1
- 125000005946 imidazo[1,2-a]pyridyl group Chemical group 0.000 description 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 150000002485 inorganic esters Chemical class 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- VDBNYAPERZTOOF-UHFFFAOYSA-N isoquinolin-1(2H)-one Chemical compound C1=CC=C2C(=O)NC=CC2=C1 VDBNYAPERZTOOF-UHFFFAOYSA-N 0.000 description 1
- 125000004628 isothiazolidinyl group Chemical group S1N(CCC1)* 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 1
- 125000004458 methylaminocarbonyl group Chemical group [H]N(C(*)=O)C([H])([H])[H] 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 150000003014 phosphoric acid esters Chemical class 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 230000000291 postprandial effect Effects 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 239000002423 protozoacide Substances 0.000 description 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- 125000005344 pyridylmethyl group Chemical group [H]C1=C([H])C([H])=C([H])C(=N1)C([H])([H])* 0.000 description 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000001422 pyrrolinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000003893 regulation of appetite Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Child & Adolescent Psychology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Pyrrole Compounds (AREA)
- Indole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0021831.3A GB0021831D0 (en) | 2000-09-06 | 2000-09-06 | Chemical compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200301013B true ZA200301013B (en) | 2004-05-05 |
Family
ID=9898927
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200301013A ZA200301013B (en) | 2000-09-06 | 2003-02-05 | Bicyclic pyrrolyl amides as glucogen phosphorylase inhibitors. |
Country Status (31)
| Country | Link |
|---|---|
| US (1) | US20030232875A1 (fr) |
| EP (1) | EP1317459B1 (fr) |
| JP (1) | JP2004508376A (fr) |
| KR (1) | KR100802369B1 (fr) |
| CN (2) | CN1264846C (fr) |
| AT (1) | ATE263772T1 (fr) |
| AU (2) | AU2001282833B2 (fr) |
| BG (1) | BG107624A (fr) |
| BR (1) | BR0113606A (fr) |
| CA (1) | CA2417594A1 (fr) |
| CZ (1) | CZ2003616A3 (fr) |
| DE (1) | DE60102710T2 (fr) |
| DK (1) | DK1317459T3 (fr) |
| EE (1) | EE200300083A (fr) |
| ES (1) | ES2217183T3 (fr) |
| GB (1) | GB0021831D0 (fr) |
| HK (1) | HK1055299A1 (fr) |
| HU (1) | HUP0400784A3 (fr) |
| IL (1) | IL154291A0 (fr) |
| IS (1) | IS2110B (fr) |
| MX (1) | MXPA03001512A (fr) |
| NO (1) | NO20031024D0 (fr) |
| NZ (1) | NZ524011A (fr) |
| PL (1) | PL361024A1 (fr) |
| PT (1) | PT1317459E (fr) |
| RU (1) | RU2003104013A (fr) |
| SK (1) | SK2592003A3 (fr) |
| TR (1) | TR200401659T4 (fr) |
| UA (1) | UA73781C2 (fr) |
| WO (1) | WO2002020530A1 (fr) |
| ZA (1) | ZA200301013B (fr) |
Families Citing this family (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CO5271699A1 (es) * | 2000-01-24 | 2003-04-30 | Pfizer Prod Inc | Procedimiento para el tratamiento de cardiomiopatia utilizando inhibidores de la glucogeno fosforilasa |
| PE20020856A1 (es) | 2001-02-13 | 2002-11-11 | Aventis Pharma Gmbh | 1,2,3,4-tetrahidronaftil aminas aciladas |
| TWI243164B (en) | 2001-02-13 | 2005-11-11 | Aventis Pharma Gmbh | Acylated indanyl amines and their use as pharmaceuticals |
| GB0205165D0 (en) * | 2002-03-06 | 2002-04-17 | Astrazeneca Ab | Chemical compounds |
| GB0205166D0 (en) * | 2002-03-06 | 2002-04-17 | Astrazeneca Ab | Chemical compounds |
| GB0205162D0 (en) * | 2002-03-06 | 2002-04-17 | Astrazeneca Ab | Chemical compounds |
| GB0205176D0 (en) | 2002-03-06 | 2002-04-17 | Astrazeneca Ab | Chemical compounds |
| GB0205170D0 (en) * | 2002-03-06 | 2002-04-17 | Astrazeneca Ab | Chemical compounds |
| GB0205175D0 (en) | 2002-03-06 | 2002-04-17 | Astrazeneca Ab | Chemical compounds |
| DE10215908B4 (de) * | 2002-04-11 | 2005-08-18 | Aventis Pharma Deutschland Gmbh | Acyl-3-carboxyphenyl-harnstoffderivate und deren Verwendung als Arzneimittel |
| IL164249A0 (en) * | 2002-04-11 | 2005-12-18 | Aventis Pharma Gmbh | Acyl-3-carboxphenylurea derivatives, processes forpreparing them and their use |
| US7057046B2 (en) * | 2002-05-20 | 2006-06-06 | Bristol-Myers Squibb Company | Lactam glycogen phosphorylase inhibitors and method of use |
| DE10225635C1 (de) * | 2002-06-07 | 2003-12-24 | Aventis Pharma Gmbh | N-Benzoylureido-Zimtsäurederivate, Verfahren zu deren Herstellung und deren Verwendung |
| DE50311954D1 (de) * | 2002-06-17 | 2009-11-12 | Saltigo Gmbh | Verfahren zur Herstellung von mono-N-sulfonylierten Diaminen |
| MXPA05000055A (es) * | 2002-07-11 | 2005-04-08 | Aventis Pharma Gmbh | Acilureas sustituidas con urea y uretano, metodos para su produccion y su uso. |
| EP1388535A1 (fr) * | 2002-08-07 | 2004-02-11 | Aventis Pharma Deutschland GmbH | Arylcycloalkylamines acylés et leurs utilisations comme produits pharmaceutiques |
| US7186735B2 (en) | 2002-08-07 | 2007-03-06 | Sanofi-Aventis Deutschland Gmbh | Acylated arylcycloalkylamines and their use as pharmaceuticals |
| GB0222909D0 (en) | 2002-10-03 | 2002-11-13 | Astrazeneca Ab | Novel process and intermediates |
| GB0222912D0 (en) * | 2002-10-03 | 2002-11-13 | Astrazeneca Ab | Novel process and intermediates |
| WO2004041780A2 (fr) * | 2002-11-07 | 2004-05-21 | Pfizer Products Inc. | Agents antidiabetiques |
| WO2004092158A1 (fr) * | 2003-04-17 | 2004-10-28 | Pfizer Products Inc. | Derives de carboxamide en tant qu'agents anti-diabetiques |
| UA84146C2 (ru) * | 2003-05-21 | 2008-09-25 | Прозидион Лимитед | Амиды пирролопиридин-2-карбоновой кислоты как ингибиторы гликогенфосфорилазы, способ их получения, фармацевтическая композиция и их применение как терапевтических агентов для лечения заболеваний |
| US7405210B2 (en) | 2003-05-21 | 2008-07-29 | Osi Pharmaceuticals, Inc. | Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase |
| WO2004113345A1 (fr) * | 2003-06-20 | 2004-12-29 | Japan Tobacco Inc. | Compose de pyrrole condense et son utilisation comme medicament |
| GB0318463D0 (en) * | 2003-08-07 | 2003-09-10 | Astrazeneca Ab | Chemical compounds |
| GB0318464D0 (en) * | 2003-08-07 | 2003-09-10 | Astrazeneca Ab | Chemical compounds |
| GB0319690D0 (en) * | 2003-08-22 | 2003-09-24 | Astrazeneca Ab | Chemical compounds |
| GB0319759D0 (en) * | 2003-08-22 | 2003-09-24 | Astrazeneca Ab | Chemical compounds |
| WO2005020985A1 (fr) * | 2003-08-29 | 2005-03-10 | Astrazeneca Ab | Derives d'indolamide possedant une activite inhibitrice de la glycogene phosphorylase |
| WO2005020986A1 (fr) * | 2003-08-29 | 2005-03-10 | Astrazeneca Ab | Derives d'amide heterocyclique ayant une activite inhibitrice de la glycogene phosphorylase |
| GB0320422D0 (en) * | 2003-08-30 | 2003-10-01 | Astrazeneca Ab | Chemical compounds |
| PL380887A1 (pl) | 2003-12-29 | 2007-04-02 | Sepracor Inc. | Pirolowe i pirazolowe inhibitory DAAO |
| US7453002B2 (en) | 2004-06-15 | 2008-11-18 | Bristol-Myers Squibb Company | Five-membered heterocycles useful as serine protease inhibitors |
| WO2006053274A2 (fr) * | 2004-11-15 | 2006-05-18 | Bristol-Myers Squibb Company | Derives de tetraline 2-amino-1-fonctionnalises et inhibiteurs correspondants de glycogene phosphorylase |
| WO2006055462A1 (fr) * | 2004-11-15 | 2006-05-26 | Bristol-Myers Squibb Company | Derives 2-amino-4- tetraline fonctionnalisee et inhibiteurs de la glycogene phosphorylase associes |
| US7223786B2 (en) | 2004-11-15 | 2007-05-29 | Bristol-Myers Squibb Company | 2-aminonaphthalene derivatives and related glycogen phosphorylase inhibitors |
| WO2006055463A2 (fr) * | 2004-11-15 | 2006-05-26 | Bristol-Myers Squibb Company | Derives de 2-amino-3-tetraline fonctionnalisee et inhibiteurs de la glycogene phosphorylase associes |
| ES2309822T3 (es) | 2004-12-02 | 2008-12-16 | Prosidion Limited | Derivado de amida del acido pirrolopiridina-2-carboxilico util como inhibidor de la glucogeno-fosforilasa. |
| US20090298745A1 (en) * | 2004-12-02 | 2009-12-03 | Gerard Hugh Thomas | Treatment of Diabetes with Glycogen Phosphorylase Inhibitors |
| US8338614B2 (en) * | 2005-01-19 | 2012-12-25 | Merck, Sharp & Dohme Corp. | Tertiary carbinamines having substituted heterocycles which are active as β-secretase inhibitors for the treatment of alzheimer's disease |
| JP2008528666A (ja) * | 2005-02-05 | 2008-07-31 | アストラゼネカ アクチボラグ | グリコーゲンホスホリラーゼ阻害活性を有するインダンアミド誘導体 |
| MX2007009438A (es) * | 2005-02-05 | 2007-08-16 | Astrazeneca Ab | Compuestos quimicos. |
| US20070203111A1 (en) | 2006-01-06 | 2007-08-30 | Sepracor Inc. | Cycloalkylamines as monoamine reuptake inhibitors |
| CN104276955A (zh) | 2006-01-06 | 2015-01-14 | 赛诺维信制药公司 | 基于四氢萘酮的单胺再摄取抑制剂 |
| ES2555315T3 (es) | 2006-03-31 | 2015-12-30 | Sunovion Pharmaceuticals Inc. | Preparación de amidas y aminas quirales |
| PE20110235A1 (es) | 2006-05-04 | 2011-04-14 | Boehringer Ingelheim Int | Combinaciones farmaceuticas que comprenden linagliptina y metmorfina |
| US7884124B2 (en) | 2006-06-30 | 2011-02-08 | Sepracor Inc. | Fluoro-substituted inhibitors of D-amino acid oxidase |
| US8492405B2 (en) | 2006-10-18 | 2013-07-23 | Takeda Pharmaceutical Company Limited | Glucokinase-activating fused heterocyclic compounds and methods of treating diabetes and obesity |
| US7902252B2 (en) | 2007-01-18 | 2011-03-08 | Sepracor, Inc. | Inhibitors of D-amino acid oxidase |
| MX2009012685A (es) | 2007-05-31 | 2009-12-14 | Sepracor Inc | Cicloalquilaminas sustituidas con fenilo como inhibidores de la reabsorcion de monoamina. |
| US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
| US20100152200A1 (en) * | 2008-11-17 | 2010-06-17 | The Regents Of The University Of Michigan | Alphavirus inhibitors and uses thereof |
| WO2012027331A1 (fr) | 2010-08-27 | 2012-03-01 | Ironwood Pharmaceuticals, Inc. | Compositions et procédés pour traiter ou prévenir un syndrome métabolique et des maladies et troubles associés |
| US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
| US10011637B2 (en) | 2013-06-05 | 2018-07-03 | Synergy Pharmaceuticals, Inc. | Ultra-pure agonists of guanylate cyclase C, method of making and using same |
| MX2017002610A (es) | 2014-08-29 | 2017-10-11 | Tes Pharma S R L | INHIBIDORES DE ACIDO A-AMINO-ß-CARBOXIMUCONICO SEMIALDEHIDO DESCARBOXILASA. |
| AU2016287581B2 (en) * | 2015-07-02 | 2019-06-06 | F. Hoffmann-La Roche Ag | Bicyclic lactams and methods of use thereof |
| WO2017136727A2 (fr) * | 2016-02-05 | 2017-08-10 | Denali Therapeutics Inc. | Composés, compositions et procédés |
| US20180134667A1 (en) | 2016-10-14 | 2018-05-17 | TES Pharma S.r.I. | Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase |
| EP3526219B1 (fr) | 2016-10-17 | 2021-12-15 | F. Hoffmann-La Roche AG | Lactames de pyridone bicycliques et leurs méthodes d'utilisation |
| US11072607B2 (en) | 2016-12-16 | 2021-07-27 | Genentech, Inc. | Inhibitors of RIP1 kinase and methods of use thereof |
| JP7398391B2 (ja) | 2018-04-20 | 2023-12-14 | エフ． ホフマン－ラ ロシュ アーゲー | Ｎ－［４－オキソ－２，３－ジヒドロ－１，５－ベンズオキサゼピン－３－イル］－５，６－ジヒドロ－４Ｈ－ピロロ［１，２－ｂ］ピラゾール－２－カルボキサミド誘導体及び例えば過敏性腸症候群（ＩＢＳ）を処置するためのＲＩＰ１キナーゼ阻害剤としての関連化合物 |
| MX2021005904A (es) | 2018-11-20 | 2021-09-08 | Tes Pharma S R L | Inhibidores de la ácido alfa-amino-beta-carboximucónico semialdehído descarboxilasa. |
| CA3163206A1 (fr) * | 2019-11-27 | 2021-06-03 | Riken | Inhibiteur de g9a |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3706810A (en) * | 1970-09-15 | 1972-12-19 | American Cyanamid Co | N-morpholinoalkyl-thieno(3,2-b)pyrrole-5-carboxamides |
| US4692522A (en) * | 1985-04-01 | 1987-09-08 | Merck & Co., Inc. | Benzofused lactams useful as cholecystokinin antagonists |
| US4668769A (en) * | 1985-08-02 | 1987-05-26 | Hoover Dennis J | Oxa- and azahomocyclostatine polypeptides |
| US4599198A (en) * | 1985-08-02 | 1986-07-08 | Pfizer Inc. | Intermediates in polypeptide synthesis |
| US4720503A (en) * | 1985-08-02 | 1988-01-19 | Merck & Co., Inc. | N-substituted fused-heterocyclic carboxamide derivatives as dual cyclooxygenase and lipoxygenase inhibitors |
| FR2601368B1 (fr) * | 1986-07-08 | 1989-04-07 | Synthelabo | Derives de nitrofuranne, leur preparation et leur application en therapeutique. |
| DE3629545A1 (de) * | 1986-08-30 | 1988-03-10 | Bayer Ag | Dihydropyridinverbindungen, verfahren zu ihrer herstellung und ihre verwendung |
| US4751231A (en) * | 1987-09-16 | 1988-06-14 | Merck & Co., Inc. | Substituted thieno[2,3-b]pyrrole-5-sulfonamides as antiglaucoma agents |
| ES2081747B1 (es) * | 1993-09-07 | 1997-01-16 | Esteve Labor Dr | Amidas derivadas de tienopirroles, su preparacion y su aplicacion como medicamentos. |
| US5863903A (en) * | 1994-03-09 | 1999-01-26 | Novo Nordisk A/S | Use of hydroxy alkyl piperidine and pyrrolidine compounds to treat diabetes |
| FR2723739B1 (fr) * | 1994-08-19 | 1997-02-14 | Sanofi Sa | Derives de glycinamide, procedes pour leur preparation et medicaments les contenant. |
| JP3314938B2 (ja) * | 1995-06-06 | 2002-08-19 | ファイザー・インコーポレーテッド | グリコーゲンホスホリラーゼ抑制剤としての置換されたｎ−（インドール−２−カルボニル）−グリシンアミド類および誘導体 |
| US5952322A (en) * | 1996-12-05 | 1999-09-14 | Pfizer Inc. | Method of reducing tissue damage associated with non-cardiac ischemia using glycogen phosphorylase inhibitors |
| US5998463A (en) * | 1998-02-27 | 1999-12-07 | Pfizer Inc | Glycogen phosphorylase inhibitors |
| EP1062218A1 (fr) * | 1998-03-12 | 2000-12-27 | Novo Nordisk A/S | MODULATEURS DE PROTEINE TYROSINE PHOSPHATASES (PTPases) |
| EP1088824B1 (fr) * | 1999-09-30 | 2004-01-07 | Pfizer Products Inc. | Amides de pyrrole bicycliques comme inhibiteurs du glycogène phosphorylase |
| CO5271699A1 (es) * | 2000-01-24 | 2003-04-30 | Pfizer Prod Inc | Procedimiento para el tratamiento de cardiomiopatia utilizando inhibidores de la glucogeno fosforilasa |
| US6555569B2 (en) * | 2000-03-07 | 2003-04-29 | Pfizer Inc. | Use of heteroaryl substituted N-(indole-2-carbonyl-) amides for treatment of infection |
| US7057046B2 (en) * | 2002-05-20 | 2006-06-06 | Bristol-Myers Squibb Company | Lactam glycogen phosphorylase inhibitors and method of use |
-
2000
- 2000-09-06 GB GBGB0021831.3A patent/GB0021831D0/en not_active Ceased
-
2001
- 2001-08-31 ES ES01961577T patent/ES2217183T3/es not_active Expired - Lifetime
- 2001-08-31 HU HU0400784A patent/HUP0400784A3/hu unknown
- 2001-08-31 PT PT01961577T patent/PT1317459E/pt unknown
- 2001-08-31 CN CNB018183220A patent/CN1264846C/zh not_active Expired - Fee Related
- 2001-08-31 AU AU2001282833A patent/AU2001282833B2/en not_active Ceased
- 2001-08-31 WO PCT/SE2001/001880 patent/WO2002020530A1/fr active IP Right Grant
- 2001-08-31 US US10/344,506 patent/US20030232875A1/en not_active Abandoned
- 2001-08-31 PL PL01361024A patent/PL361024A1/xx unknown
- 2001-08-31 RU RU2003104013/04A patent/RU2003104013A/ru not_active Application Discontinuation
- 2001-08-31 UA UA2003021026A patent/UA73781C2/uk unknown
- 2001-08-31 AT AT01961577T patent/ATE263772T1/de not_active IP Right Cessation
- 2001-08-31 AU AU8283301A patent/AU8283301A/xx active Pending
- 2001-08-31 EP EP01961577A patent/EP1317459B1/fr not_active Expired - Lifetime
- 2001-08-31 KR KR1020037003265A patent/KR100802369B1/ko not_active IP Right Cessation
- 2001-08-31 CA CA002417594A patent/CA2417594A1/fr not_active Abandoned
- 2001-08-31 DK DK01961577T patent/DK1317459T3/da active
- 2001-08-31 CZ CZ2003616A patent/CZ2003616A3/cs unknown
- 2001-08-31 BR BR0113606-2A patent/BR0113606A/pt not_active IP Right Cessation
- 2001-08-31 DE DE60102710T patent/DE60102710T2/de not_active Expired - Fee Related
- 2001-08-31 IL IL15429101A patent/IL154291A0/xx unknown
- 2001-08-31 SK SK259-2003A patent/SK2592003A3/sk unknown
- 2001-08-31 CN CNA2006100818966A patent/CN1896078A/zh active Pending
- 2001-08-31 EE EEP200300083A patent/EE200300083A/xx unknown
- 2001-08-31 JP JP2002525151A patent/JP2004508376A/ja not_active Withdrawn
- 2001-08-31 NZ NZ524011A patent/NZ524011A/en unknown
- 2001-08-31 MX MXPA03001512A patent/MXPA03001512A/es active IP Right Grant
- 2001-08-31 TR TR2004/01659T patent/TR200401659T4/xx unknown
-
2003
- 2003-02-05 ZA ZA200301013A patent/ZA200301013B/en unknown
- 2003-02-24 IS IS6727A patent/IS2110B/is unknown
- 2003-03-05 NO NO20031024A patent/NO20031024D0/no not_active Application Discontinuation
- 2003-03-10 BG BG107624A patent/BG107624A/bg unknown
- 2003-10-16 HK HK03107519A patent/HK1055299A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA200301013B (en) | Bicyclic pyrrolyl amides as glucogen phosphorylase inhibitors. | |
| ZA200200028B (en) | Imidazo[1,2-A]pyridine and pyrazolo[2,3-A]pyridine devatives. | |
| AU767452B2 (en) | Method of treating nitrate-induced tolerance | |
| JP2004508376A5 (fr) | ||
| CN102186479A (zh) | 用于治疗疾病的组胺受体的氨基嘧啶抑制剂 | |
| AU2006301650A1 (en) | Microangiopathy treatment and prevention | |
| ZA200606243B (en) | Imidazolo-5-yl-2-anilinopyrimidines as agents for the inhibition of cell proliferation | |
| CA2584303A1 (fr) | Nouveaux composes heterocycliques | |
| CN1307183C (zh) | 具有糖原磷酸化酶抑制活性的杂环酰胺衍生物 | |
| ZA200208674B (en) | Amino substituted dibenzothiophene derivatives for the treatment of disorders mediated by the NP Y5 receptor. | |
| ZA200406679B (en) | Heterocyclic amide derivatives as inhibitors of glycogen phosphorylase. | |
| US6495554B2 (en) | Thienopyrimidines | |
| DE102006051625A1 (de) | Kombinationstherapie substituierter Oxazolidinone | |
| RU2006136880A (ru) | Фармацевтическая композиция, содержащая производные бензодиазепина и ингибитор белка слияния rsv | |
| CN106661002A (zh) | 用于治疗炎性、代谢性、肿瘤性和自身免疫性疾病的任选稠合的、经杂环基取代的嘧啶衍生物 | |
| CN100374420C (zh) | 具有糖原磷酸化酶抑制活性的吲哚酰胺衍生物 | |
| CA2756689A1 (fr) | Traitement de la douleur liee a une osteoarthrite | |
| CA2577664A1 (fr) | Nouveaux heterocycles | |
| EP1971339A2 (fr) | Combinaison de derives de triazine et de stimulateurs de secretion d'insuline | |
| MX2011000511A (es) | Uso de derivados de pirimidil-amino-benzamida para el tratamiento de fibrosis. | |
| AU781607B2 (en) | Isoxazole derivatives to be used as phosphodiesterase VII inhibitors | |
| CN106103439A (zh) | 2,7‑二氮杂螺[3.5]壬烷化合物 | |
| AU2007315932A1 (en) | A pharmaceutical composition having antipsychotic, antidepressant or antiepiieptic activity with reduced side effect | |
| MXPA03009125A (es) | Derivados de aril (o heteroaril), azolilcarbinoles para el tratamiento de enfermedades respiratorias. | |
| AU2001237379B2 (en) | Use of benzothieno-2,3-D-pyrimidines with PDE V inhibitory effect for the treatment of erectile dysfunction |